TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07654361: Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 3600 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07654361 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07654361 Rescue Dossier →